SEC Form 4 · accession 0001447028-26-000052

Arbutus Biopharma Corp · ABUS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Financial Officer

Period of report

Sep 18, 2026

Accepted (ET)

Sep 23, 2026 · 8:31 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001447028

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Shares	Sep 18, 2026	M	265,625	$3.49	A	339,125	D
Common Shares	Sep 18, 2026	M	27,475	$4.39	A	366,600	D
Common Shares	Sep 18, 2026	F	206,637	$5.07	D	159,963	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F2	$3.49	Sep 18, 2026	M	265,625	D	—	Mar 31, 2035	Common Shares	265,625	484,375	D
Stock Option (Right to Buy)^F3	$4.39	Sep 18, 2026	M	27,475	D	—	Feb 2, 2036	Common Shares	27,475	160,925	D

F1The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 206,637 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices.
F2The option, representing a right to purchase a total of 750,000 shares, vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the March 31, 2025 grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.
F3The option, representing a right to purchase a total of 188,400 shares, vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 2, 2026 grant date, subject to the Reporting Person's continuous service as of each vesting date.